Rankings
▼
Calendar
KNSA FY 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$39M
Gross Profit
$29M
76.4% margin
Operating Income
-$157M
-406.4% margin
Net Income
-$158M
-409.7% margin
EPS (Diluted)
$-2.30
Cash Flow
Operating Cash Flow
-$126M
Free Cash Flow
-$147M
Stock-Based Comp.
$25M
Balance Sheet
Total Assets
$233M
Total Liabilities
$48M
Stockholders' Equity
$185M
Cash & Equivalents
$122M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$39M
$0
—
Gross Profit
$29M
-$4M
+873.8%
Operating Income
-$157M
-$157M
+0.5%
Net Income
-$158M
-$161M
+2.1%
← Q4 2020
All Quarters
Q1 2021 →